{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:41:05Z","timestamp":1780605665592,"version":"3.54.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01564-1","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:47:11Z","timestamp":1753922831000},"page":"764-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics, efficacy and safety of palbociclib and fulvestrant in a patient with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with end-stage renal disease undergoing hemodialysis: A case report"],"prefix":"10.1007","volume":"43","author":[{"given":"Toshiaki","family":"Takakura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyo K.","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"1","key":"1564_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/bdd.2510160104","volume":"16","author":"MV Mac-Kay","year":"1995","unstructured":"Mac-Kay MV, Fernandez IP, Herrera CJ, Sancez BJ (1995) An in vitro study of the influence of a drug\u2019s molecular weight on its overall (Clt), diffusive (Cld) and convective (Clc) clearance through dialyzers. Biopharm Drug Dispos 16(1):23\u201335. https:\/\/doi.org\/10.1002\/bdd.2510160104","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"1564_CR2","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.kisu.2019.11.001","volume":"10","author":"R Pecoits-Filho","year":"2020","unstructured":"Pecoits-Filho R, Okpechi IG, Donner JA et al (2020) Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes. Kidney Int Suppl 10(1):e3\u2013e9. https:\/\/doi.org\/10.1016\/j.kisu.2019.11.001","journal-title":"Kidney Int Suppl"},{"issue":"2","key":"1564_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","volume":"18","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Lorusso PM, Demichele A et al (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 18(2):568\u2013576. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0509","journal-title":"Clin Cancer Res"},{"key":"1564_CR4","unstructured":"U.S. department of Health and Human Services; Food and Drug Administration (2023) Full Prescribing Information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/207103s017s018lbl.pdf. Accessed 02 Apr 2025"},{"key":"1564_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00280-020-04163-4","volume":"86","author":"Y Yu","year":"2020","unstructured":"Yu Y, Hoffman J, Plotka A, O\u2019Gorman M, Shi H, Wang D (2020) Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function. Cancer Chemother Pharmacol 86:701\u2013710. https:\/\/doi.org\/10.1007\/s00280-020-04163-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"1564_CR6","unstructured":"U.S. department of Health and Human Services; Food and Drug Administration (2023) Full Prescribing Information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/207103s017s018lbl.pdf. Accessed 02 Apr 2025"},{"key":"1564_CR7","unstructured":"U.S. department of Health and Human Services; Food and Drug Administration (2021) Full Prescribing Information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021344s044lbl.pdf. Accessed 02 Apr 2025."},{"key":"1564_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-006-9243-7","volume":"100","author":"T Langenegger","year":"2006","unstructured":"Langenegger T, Wahl P, Schiesser D, Th\u00fcrlimann B (2006) Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. Breast Cancer Res Treat 100:177\u2013181. https:\/\/doi.org\/10.1007\/s10549-006-9243-7","journal-title":"Breast Cancer Res Treat"},{"key":"1564_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F et al (2015) Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373:209\u2013219. https:\/\/doi.org\/10.1056\/NEJMoa1505270","journal-title":"N Engl J Med"},{"key":"1564_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/cas.12932","volume":"107","author":"K Tamura","year":"2016","unstructured":"Tamura K, Mukai H, Naito Y et al (2016) Phase I study of palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, in Japanese patients. Cancer Sci 107:755\u2013773. https:\/\/doi.org\/10.1111\/cas.12932","journal-title":"Cancer Sci"},{"issue":"9","key":"1564_CR11","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/jcph.902","volume":"57","author":"W Sun","year":"2017","unstructured":"Sun W, O\u2019Dwyer PJ, Finn RS et al (2017) Characterization of neutropenia in advanced cancer patients following palbociclib treatment using a population pharmacokinetic-pharmacodynamic modeling and simulation approach. J Clin Pharmacol 57(9):1159\u20131173. https:\/\/doi.org\/10.1002\/jcph.902","journal-title":"J Clin Pharmacol"},{"key":"1564_CR12","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/annonc\/mdq249","volume":"21","author":"S Ohno","year":"2010","unstructured":"Ohno S, Rai Y, Iwata H et al (2010) Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol 21:2342\u20132347. https:\/\/doi.org\/10.1093\/annonc\/mdq249","journal-title":"Ann Oncol"},{"issue":"4","key":"1564_CR13","first-page":"201","volume":"19","author":"F Keller","year":"1983","unstructured":"Keller F, Wilms H, Schultze G, Offerman G, Molzahn M (1983) Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodialysis. Clin Nephrol 19(4):201\u2013205","journal-title":"Clin Nephrol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01564-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01564-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01564-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:42Z","timestamp":1760195022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01564-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01564-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient provided written informed consent and the study protocols were approved by Kindai University Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"The patient declared to consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of medical data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hidetoshi Hayashi: Grants or contracts from Pfizer R & D Japan G.K., Pfizer Japan Inc., AstraZeneca K.K.; payment or honoraria from Pfizer Japan Inc., AstraZeneca K.K.; advisory board roles from AstraZeneca K.K. The remaining authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}